Polycystic Ovarian Syndrome (PCOS) Therapeutics Market

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Overview

Polycystic ovarian syndrome or PCOS refers to an endocrine disorder that is commonly found in women of reproductive age. Fertility related issues are the most common symptoms of polycystic ovarian syndrome. This disease is marked by several other symptoms as well, such as anovulation, insulin resistance, obesity, hirsutism, menstrual irregularities, and acne. Increased prevalence of this condition across the globe is expected to trigger growth of the global polycystic ovarian syndrome (PCOS) therapeutics market over the timeframe of analysis, from 2020 to 2030.

Drugs, surgery, and region are the three important parameters based on which the global polycystic ovarian syndrome (PCOS) therapeutics market has been classified.

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Notable Developments

The global polycystic ovarian syndrome (PCOS) therapeutics market is considered as a highly fragmented one that is marked with the presence of quite a few regional players. The market players are focusing more on research and development activities to bring on innovative products and gain competitive advantage.

Some of the prominent organizations in the global polycystic ovarian syndrome (PCOS) therapeutics market comprise the below-mentioned:

• Reliance Life Sciences Pvt. Ltd
• Merck KGaA
• Crinetics Pharmaceuticals, Inc.
• Ferring Pharmaceuticals, Inc.
• Neurocrine Biosciences, Inc.
• AstraZeneca plc

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Key Trends

The global polycystic ovarian syndrome (PCOS) therapeutics market is characterized by the presence of the following restraints, drivers, and opportunities.

Alarming Rise in Diabetic and Obese People to Augur Well for the Market

One of the leading growth factors of the global polycystic ovarian syndrome (PCOS) therapeutics market is the alarming rise in the number of patients with obese condition. Increased consumption of junk food, adoption of sedentary lifestyle and lack of physical exercise all contribute toward the prevalence of obese conditions, which often results in polycystic ovarian syndrome. In addition, prevalence of diabetes is another factor likely to toward the development of the global polycystic ovarian syndrome (PCOS) therapeutics market in the years to come.

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Geographical Analysis

North America is expected to dominate the global polycystic ovarian syndrome (PCOS) therapeutics market due to high prevalence of the condition. Dominance of the region is ascribed to the presence of a large number of obese and diabetic people. North America is estimated to be followed by Europe.